Fintel reports that on January 9, 2025, B of A Securities upgraded their outlook for Globus Medical (NYSE:GMED) from Underperform to Neutral.
Analyst Price Forecast Suggests 12.50% Upside
As of December 24, 2024, the average one-year price target for Globus Medical is $97.37/share. The forecasts range from a low of $80.80 to a high of $120.75. The average price target represents an increase of 12.50% from its latest reported closing price of $86.55 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Globus Medical is 1,280MM, a decrease of 48.36%. The projected annual non-GAAP EPS is 3.01.
What is the Fund Sentiment?
There are 909 funds or institutions reporting positions in Globus Medical. This is an decrease of 4 owner(s) or 0.44% in the last quarter. Average portfolio weight of all funds dedicated to GMED is 0.34%, an increase of 8.82%. Total shares owned by institutions decreased in the last three months by 0.76% to 135,164K shares. 
The put/call ratio of GMED is 0.19, indicating a bullish outlook.
What are Other Shareholders Doing?
Janus Henderson Group holds 6,998K shares representing 6.15% ownership of the company. In its prior filing, the firm reported owning 7,385K shares , representing a decrease of 5.53%. The firm decreased its portfolio allocation in GMED by 67.16% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,561K shares representing 3.13% ownership of the company. In its prior filing, the firm reported owning 3,539K shares , representing an increase of 0.64%. The firm decreased its portfolio allocation in GMED by 1.27% over the last quarter.
IJH - iShares Core S&P Mid-Cap ETF holds 3,532K shares representing 3.11% ownership of the company. In its prior filing, the firm reported owning 3,503K shares , representing an increase of 0.81%. The firm decreased its portfolio allocation in GMED by 3.82% over the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 2,827K shares representing 2.49% ownership of the company. In its prior filing, the firm reported owning 2,833K shares , representing a decrease of 0.22%. The firm decreased its portfolio allocation in GMED by 4.90% over the last quarter.
Jpmorgan Chase holds 2,605K shares representing 2.29% ownership of the company. In its prior filing, the firm reported owning 2,636K shares , representing a decrease of 1.19%. The firm increased its portfolio allocation in GMED by 975.81% over the last quarter.
Globus Medical Background Information
(This description is provided by the company.)
Based in Audubon, Pennsylvania, Globus Medical, Inc. was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
